Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
USRM | US
0
0%
Healthcare
Biotechnology
31/03/2023
21/10/2024
0.00
0.00
0.00
0.00
U.S. Stem Cell Inc. a biotechnology company engages in the discovery development and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell a patient-derived cell therapy for the treatment of acute myocardial infarction chronic heart ischemia and lower limb ischemia. Its pipeline products include MyoCell SDF-1 an autologous muscle-derived cellular therapy for enhancing cardiac function in chronic heart failure patients. The company is also developing MyoCath a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition it provides physician and patient based regenerative medicine/cell therapy training cell collection and cell storage services; and cell collection and treatment kits for humans and animals as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological autoimmune orthopedic and degenerative diseases. The company also offers various courses for physicians and other health care professionals. The company was formerly known as Bioheart Inc. and changed its name to U.S. Stem Cell Inc. in October 2015. U.S. Stem Cell Inc. was incorporated in 1999 and is headquartered in Sunrise Florida.
View LessPositive Momentum
Low Debt to Equity (< 0.25)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
0.0%1 month
0.0%3 months
0.0%6 months
0.0%-
-
-
-0.61
131.50
-6.33
109.76
-
-1.87M
64.15K
64.15K
-
-1.87K
-
-15.30
-
0.06
-
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0
Range1M
0.00
Range3M
0.00
Rel. volume
0.11
Price X volume
1.00
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
EFTR | EFTR | Biotechnology | 0.0012 | 5.64K | 0.00% | n/a | 2315.36% |
Calithera Biosciences Inc | CALA | Biotechnology | 0.001 | 4.87K | -50.00% | n/a | 8.17% |
XOMAP | XOMAP | Biotechnology | 26.24 | 0 | -0.23% | 26.27 | 121.93% |
XOMA Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock | XOMAO | Biotechnology | 25.5992 | 0 | 0.02% | 25.57 | 121.93% |
SABSW | SABSW | Biotechnology | 0.0534 | 0 | 8.54% | 0.17 | 11.58% |
Revolution Medicines Inc. Warrant | RVMDW | Biotechnology | 0.1195 | 0 | 18.32% | n/a | 5.40% |
REVBW | REVBW | Biotechnology | 0.0129 | 0 | -3.01% | n/a | 0.00% |
Rocket Pharmaceuticals Inc. Warrant | RCKTW | Biotechnology | 0.0666 | 0 | -6.06% | n/a | 0.00% |
OCEAW | OCEAW | Biotechnology | 0.0398 | 0 | 2.58% | n/a | -16.02% |
Nutriband Inc. Warrant | NTRBW | Biotechnology | 1.15 | 0 | 9.52% | n/a | 1.72% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
No data |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -6.33 | 0.53 | Cheaper |
Ent. to Revenue | 109.76 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | - | 15.55 | - |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | - | 72.80 | - |
Debt to Equity | -0.61 | -1.23 | Expensive |
Debt to Assets | 131.50 | 0.25 | Expensive |
Market Cap | 64.15K | 3.66B | Emerging |